Shionogi & Co.

Shionogi & Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and over‑the‑counter medicines. Its therapeutic portfolio covers infectious diseases, pain and central nervous system disorders, metabolic and cardiovascular conditions, and oncology. The company also produces vaccines, diagnostics, and consumer health products for both domestic and international markets. In the United States, its operations are conducted through Shionogi Inc., which manages clinical development, regulatory affairs, and commercialization of Shionogi‑originated compounds. Shionogi maintains research and development centers in Japan and the United States, and it has a presence across Asia and Europe through various subsidiaries and distribution partners.

In October 2020, the Taiwanese subsidiary of Shionogi experienced a ransomware attack carried out by the REvil group, which encrypted systems and exfiltrated data; the attackers published a directory screenshot and a small sample of PDF files as proof of access. Shionogi confirmed that the breach did not compromise any information related to its coronavirus vaccine development efforts. The incident highlighted the cybersecurity risks faced by pharmaceutical firms with global operations and prompted the company to reinforce its network defenses. No further details about the scope of the data exfiltration were disclosed in public statements.

Shionogi is recognized for its specialization in antiviral therapeutics, notably the influenza drug baloxavir marboxil (Xofluza) and contributions to HIV treatment regimens containing dolutegravir. The company invests heavily in innovative drug discovery programs and collaborates with academic institutions and biotech partners to advance its pipeline. As a publicly listed entity on the Tokyo Stock Exchange, Shionogi adheres to the regulatory standards of Japan’s PMDA, the U.S. FDA, and the European EMA, ensuring compliance across its development and commercialization activities. Its corporate structure includes wholly owned subsidiaries such as Shionogi Inc. in the United States and Shionogi Taiwan, the entity affected by the 2020 cyber incident.

Shionogi & Co., Ltd. serves as the parent company overseeing its domestic and international operations, with Shionogi Inc. functioning as its U.S. subsidiary for development and commercialization purposes. The company’s organizational framework also encompasses regional affiliates that support manufacturing, sales, and pharmacovigilance activities. Ownership remains publicly traded, with shares held by institutional and individual investors in Japan and abroad. This structure enables Shionogi to coordinate global research initiatives while maintaining localized market responsiveness.